FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world data for EKTERLY (sebetralstat) at the American Academy of Allergy, Asthma & Immunology Annual Meeting 2026, reinforcing the therapy’s role in hereditary angioedema (HAE) management. Accepted abstracts include placebo-controlled trial analyses, treatment pattern insights, and patient burden research, highlighting the expanding scientific and clinical evidence base supporting the first oral on-demand therapy for acute HAE attacks.
Science Significance
The scientific importance of the presentations lies in advancing understanding of plasma kallikrein inhibition and oral acute-attack intervention. Data from placebo-controlled trials examine response drivers and efficacy determinants for sebetralstat, offering insights into pharmacodynamic activity and attack resolution kinetics. Additional findings from the KONFIDENT-S study evaluate real-world on-demand treatment patterns, helping define optimal dosing timing and symptom control outcomes. Investigators also presented burden-of-disease survey results, demonstrating the clinical severity, unpredictability, and life-threatening nature of HAE swelling episodes. Together, the datasets strengthen scientific confidence that rapid, oral kallikrein blockade can shorten attack duration and improve functional recovery without injection-related limitations.
Regulatory Significance
From a regulatory perspective, the data support lifecycle expansion and global filing strategies for sebetralstat. The therapy is already approved across multiple regions for acute HAE attacks in patients aged 12 and older, and new evidence may inform label updates, pediatric indications, and post-marketing commitments. Planned regulatory submissions to expand use into children aged 2–11 signal continued dialogue with health authorities on safety, dosing, and pediatric risk management plans. Clinical evidence presented at major congresses such as AAAAI also contributes to regulatory transparency, pharmacovigilance monitoring, and real-world effectiveness validation under GCP and post-authorization frameworks.
Business Significance
Advertisement
Commercially, EKTERLY represents a differentiated asset within the rare disease therapeutics market. As the first and only oral on-demand treatment for HAE, it addresses longstanding barriers associated with injectable therapies, including administration burden and delayed dosing. Conference visibility strengthens brand adoption among allergists and immunologists while supporting payer engagement through outcomes data. The therapy’s multi-region approvals and anticipated pediatric expansion position KalVista to capture broader market share and establish sebetralstat as a foundational HAE therapy worldwide. Continued clinical dissemination also enhances partnership and licensing value within the specialty pharma ecosystem.
Patients’ Significance
For patients living with hereditary angioedema, the implications are substantial. HAE attacks cause painful, debilitating, and sometimes life-threatening tissue swelling, often affecting the airway, abdomen, or extremities. Rapid treatment is essential to prevent escalation. Oral sebetralstat offers needle-free, self-administered attack control, enabling faster intervention at symptom onset. Real-world and survey data presented at AAAAI highlight the psychological, social, and functional burden of unpredictable attacks, reinforcing the importance of accessible acute therapies. Improved attack resolution and reduced treatment anxiety can significantly enhance quality of life, independence, and long-term disease confidence.
Policy Significance
Health policy stakeholders are increasingly focused on rare disease access, home-based care models, and treatment equity. Oral acute therapies like sebetralstat may reduce emergency visits, infusion center reliance, and hospitalizations, supporting cost-containment and decentralized care delivery. Policymakers must balance reimbursement for innovative orphan drugs with sustainable healthcare spending, particularly as genetic and immunologic rare disease therapies expand. Data presented at global congresses help inform treatment guidelines, payer coverage frameworks, and rare disease awareness initiatives aimed at earlier diagnosis and intervention.
KalVista’s AAAAI 2026 data presentations reinforce the growing clinical and scientific momentum behind oral plasma kallikrein inhibition in hereditary angioedema. By combining controlled trial evidence, real-world utilization insights, and patient burden analyses, the company is strengthening the therapeutic value proposition of sebetralstat. As regulatory expansion and global adoption accelerate, EKTERLY has the potential to redefine acute HAE attack management through rapid, oral, patient-centric intervention, marking a significant milestone in rare immunologic disease care.
Source: KalVista Pharmaceuticals, Inc. press release
